Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation
Ascletis Pharma Inc (AP HK) which specialises in developing drugs to treat HCV (hepatitis C virus), HIV and liver cancer, is the first pre-profit...
914 Views
Trade Risks Start to Impact, as China Biotech Ambitions Grow…
Cyclical indicators are softening this month - new orders index for the Philly Fed fell nearly 23 points while Japan’s PMI new export orders...
257 Views
WuXi Biologics: Pass on This Valuation
The company's underwriters have announced a price range of HK$18.60 - HK$20.60 which implies a market cap of US$2.7-3.0 billion. We recommend...
920 Views
3SBio: A Leading, Pure-Play Chinese (HK-Listed) Biotechnology Company (Part II)
This is the part II of collaboration on 3SBio Inc (1530 HK) between Dr. Bhavneesh Sharma, MD, MBA and Luan NguyenDCF analysisWe have performed a...
448 Views
3SBio: A Leading, Pure-Play Chinese (HK-Listed) Biotechnology Company (Part I)
3SBio shares are trading below 52-week high of HKD 11.48 and appear to have 30-40% upside. 3SBio is one of the leading biotechnology companies in...
355 Views